Acute, High Dose Metformin Therapy at Reperfusion Decreases Infarct Size in the High-Risk Aging Heart

Elderly patients (age > 75) sustain larger infarcts with greater mortality from ST elevation myocardial infarcts (STEMI) despite successful reperfusion treatment. Elderly age remains an independent risk despite correction for clinical and angiographic variables. The elderly represent a high-risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Lauryn, Krause-Hauch, Meredith, Wang, Hao, Fatmi, Mohammad Kasim, Li, Zehui, Chen, Qun, Ren, Di, Li, Ji, Lesnefsky, Edward J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JKL International LLC 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529738/
https://www.ncbi.nlm.nih.gov/pubmed/37196121
http://dx.doi.org/10.14336/AD.2023.0205
Descripción
Sumario:Elderly patients (age > 75) sustain larger infarcts with greater mortality from ST elevation myocardial infarcts (STEMI) despite successful reperfusion treatment. Elderly age remains an independent risk despite correction for clinical and angiographic variables. The elderly represent a high-risk population and may benefit from treatment in addition to reperfusion alone. We hypothesized that modulation of cardiac signaling and metabolism with acute, high dose metformin given at reperfusion would exhibit additional cardioprotection. Using a translational aging murine model (22-24-month C57BL/6J mice) of in vivo STEMI (45 min artery occlusion with reperfusion for 24 hours); treatment acutely at reperfusion by high dose metformin decreased infarct size and enhanced contractile recovery, demonstrating cardioprotection in the high-risk aging heart.

Ejemplares similares